News | ECG Wireless Remote Access | May 04, 2020

Cardiac Insight Launches New Telehealth Solution for Cardiology Practices with [email protected] ECG Test Kit

Direct-to-patient Cardea Solo wearable ECG speeds clinical decision-making while removing costly and time-consuming outsourcing of data analysis 

Cardiac Insight's Heart@Home ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor.

Cardiac Insight's [email protected] ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response using arrhythmia diagnosis technology of the wearable Cardea Solo Sensor. 

May 4, 2020 — Cardiac Insight Inc., a U.S.-based digital healthcare innovator specializing in body-worn sensor technology and automated electrocardiogram (ECG)-analysis software, announced the [email protected] ECG Test Kit can help address new telehealth demands placed on cardiology practices by the COVID-19 response.

The kit enables physicians to prescribe the proven arrhythmia diagnosis technology of the Cardea Solo Sensor which is express-shipped directly from Cardiac Insight to the patient’s home, along with easy-to-follow instructions. The patient simply mails the single-use sensor to the cardiologist’s office in the included shipping envelope after wearing the sensor for the prescribed time period.

Clinicians can immediately retrieve data from the device to inform diagnoses using Cardea Solo’s smart cable and robust, proprietary algorithm-based ECG software, provided free of charge with the purchase of the [email protected] ECG Test Kit. The entire process in the office takes less than five minutes to create a complete ECG report.

“In these unprecedented times, while legacy ECG service companies employing decades-old technology are scaling back operations and decreasing services, Cardiac Insight is innovating and acting quickly to provide cardiologists and their patients with essential and easy-to-use telehealth options. As a single-use sensor, Cardea Solo affords patients, doctors and clinical staff more infection control protections with no need for cleaning or transferring devices between patients,”said Robert Odell, president and chief operating officer of Cardiac Insight. “We believe the new [email protected] program further strengthens the physician and patient relationship in a time when trust and privacy is more critical than ever, by fostering direct interactions and removing third-party data analysis vendors from the equation.”

The Cardea Solo ECG System allows physicians to reduce the diagnostic timeline of patients potentially at risk of cardiac arrhythmias from weeks to just days. These arrhythmias include atrial fibrillation (AFib). If left undiagnosed, AFib can lead to debilitating stroke, heart failure and sudden cardiac death.

The Cardea Solo [email protected] ECG Test Kit is currently available for office-based practices and hospital clinics in the U.S. and is designed to address the needs of Electrophysiologists, Cardiologists, Internal Medicine and Family Medicine physicians. Comprehensive program information and telehealth resources are available on request here.

For more information: www.cardiacinsightinc.com

Related Content

Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...